Recently, an oral form of Decitabine in combination with cytidine deaminase (CDA) inhibitor Cedazuridine, termed C-DEC, has been approved as the first oral HMA, and its possible role in MDS and secondary AML along with other hematologic malignancies is of active interest [19]. This evidence concerns the gene CDA and hematologic disorder.